Research

Everything we publish in one place: company stock analysis with a clear rating, coverage of what changes in SEC filings, short squeeze studies and backtests of trading ideas.

241 articles

Equity Research

Company-level stock analysis, valuation, margins, balance sheet risk, and rating rationale.

Nov 11, 2026CleanSpark Stock Analysis: Buy or Sell? Valuation, Debt & Cash Burn
Nov 10, 2026Brookfield Infrastructure Partners Stock Analysis: Buy or Sell? Valuation, Leverage & Cash Flow
Nov 10, 2026e.l.f. Beauty Stock Analysis: Buy or Sell? Valuation, Margins, Growth & Tariffs
Nov 9, 2026Viavi Solutions Stock Analysis: Buy or Sell? Valuation, Margins & FCF

View all Equity Research →

161 articles

The Scorecard

Post-publication reviews that check what happened after earlier Buy and Sell calls.

Nov 11, 20263 Month Update: ADTN Sell — Correct so far
Nov 9, 20263 Month Update: WGS Sell — Correct so far
Nov 5, 20264 Month Update: MTZ Sell — Correct so far
Nov 4, 20263 Month Update: VNOM Sell — Incorrect so far

View all The Scorecard →

108 articles

SEC What Changed

Daily filing-change notes comparing new 10-K language with prior-year disclosures.

View all SEC What Changed →

13 articles

Weekly Performance

Friday performance updates for the public LF0 research track record.

Nov 6, 2026Weekly Performance, Nov 6, 2026: 80.2%, 22.4%
Oct 30, 2026Weekly Performance, Oct 30, 2026: 73.7%, 11.9%
Oct 23, 2026Weekly Performance, Oct 23, 2026: 85.9%, 17.2%
Oct 16, 2026Weekly Performance, Oct 16, 2026: 80%, +11.7%

View all Weekly Performance →

Equity Research
CLSK
SELL
CleanSpark Stock Analysis: Buy or Sell? Valuation, Debt & Cash Burn
Nov 11, 2026
CleanSpark (CLSK) carries a Sell rating because its scale has not yet translated into durable earnings or cash generation. Rich valuation, heavy debt, and negative operating cash flow keep the recovery case from fully showing up in the numbers.
Read note
The Scorecard
ADTN
SELL
The Scorecard: 3 Month Update: ADTN Sell — Correct so far
Nov 11, 2026
Revisiting our Sell call on ADTN: entry $7.76, latest $4.41, -43.2%.
Read note
SEC What Changed
BMNR, BV, ESMR, SBH, SWKS, TDG
E-Smart (ESMR) 10-K: Risk Factors Changes Lead 10 November 2026 Filing Roundup
Nov 10, 2026
E-Smart (ESMR)’s Risk Factors section changed the most among 7 companies that filed 10-Ks on 10 November 2026, each compared against its prior-year filing.
Read note
Equity Research
BIP
HOLD
Brookfield Infrastructure Partners Stock Analysis: Buy or Sell? Valuation, Leverage & Cash Flow
Nov 10, 2026
Brookfield Infrastructure Partners (BIP) carries a Hold rating because its contracted, regulated asset base is high quality, but leverage and weak free cash flow limit upside. The stock looks fairly valued at 10.2x EV/EBITDA, leaving little margin of safety for investors.
Read note
Equity Research
ELF
HOLD
e.l.f. Beauty Stock Analysis: Buy or Sell? Valuation, Margins, Growth & Tariffs
Nov 10, 2026
e.l.f. Beauty (ELF) is rated Hold as strong growth is already priced in. The stock’s rich valuation leaves little room for a margin slip, especially after tariff pressure hit profitability.
Read note
Equity Research
VIAV
HOLD
Viavi Solutions Stock Analysis: Buy or Sell? Valuation, Margins & FCF
Nov 9, 2026
VIAVI Solutions (VIAV) is rated Hold as strong revenue growth and solid free cash flow support the shares, but the market already prices in a cleaner earnings recovery. Customer concentration and execution remain the key risks, even with net debt at just 0.45x EBITDA.
Read note
Equity Research
GCT
HOLD
GigaCloud Technology Stock Analysis: Buy or Sell? Valuation, Cash Flow & Insider Selling
Nov 9, 2026
GigaCloud Technology Inc. (GCT) is rated Hold as growth remains strong, but the shares already discount much of it. Valuation looks fair to slightly rich, while insider selling and cash-flow conversion remain key watch items.
Read note
Equity Research
VOYG
STRONG SELL
Voyager Technologies Stock Analysis: Buy or Sell? Valuation, Cash Burn & Leverage
Nov 9, 2026
Voyager Technologies (VOYG) is rated STRONG SELL as revenue growth has not offset severe cash burn and heavy leverage. The stock trades at a rich valuation while levered free cash flow remains deeply negative.
Read note
The Scorecard
WGS
SELL
The Scorecard: 3 Month Update: WGS Sell — Correct so far
Nov 9, 2026
Revisiting our Sell call on WGS: entry $77.88, latest $62.37, -19.9%.
Read note
Equity Research
ABCL
STRONG SELL
AbCellera Biologics Stock Analysis: Buy or Sell? Valuation & Cash Burn
Nov 9, 2026
AbCellera Biologics Inc. (ABCL) is rated STRONG SELL as valuation still assumes a much faster clinical and commercial ramp than current results support. Despite a large cash balance, ongoing cash burn and rich revenue multiples leave little margin of safety.
Read note

Waitlist

Join the lf0 premium research waitlist.

More detailed equity research, scorecards, and performance analysis are coming. Add your email to be first in line.

Join the Waitlist